Geode Capital Management
VRCA icon

Geode Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Geode Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$615K Sell
128,298
-9,862
-7% -$51.4K ﹤0.01% 3487
2026
Q2 		$846K Sell
138,160
-757
-0.5% -$4.72K ﹤0.01% 3420
2026
Q1 		$735K Buy
138,917
+71,258
+105% +$456K ﹤0.01% 3455
2025
Q4 		$562K Hold
67,659
– – ﹤0.01% 3547
2025
Q3 		$292K Buy
67,659
+3,043
+5% +$18.4K ﹤0.01% 3806
2025
Q2 		$343K Sell
64,616
-37,233
-37% -$200K ﹤0.01% 3675
2025
Q1 		$450K Buy
101,849
+54,122
+113% +$350K ﹤0.01% 3581
2024
Q4 		$334K Buy
47,727
+2,179
+5% +$24K ﹤0.01% 3727
2024
Q3 		$661K Sell
45,548
-788
-2% -$35.5K ﹤0.01% 3499
2024
Q2 		$3.38M Buy
46,336
+1,405
+3% +$108K ﹤0.01% 2930
2024
Q1 		$2.66M Buy
44,931
+1,963
+5% +$108K ﹤0.01% 3005
2023
Q4 		$3.15M Buy
42,968
+1,289
+3% +$53K ﹤0.01% 2927
2023
Q3 		$1.62M Buy
41,679
+2,828
+7% +$144K ﹤0.01% 3145
2023
Q2 		$2.24M Buy
38,851
+20,763
+115% +$1.26M ﹤0.01% 3075
2023
Q1 		$1.18M Buy
18,088
+1,792
+11% +$108K ﹤0.01% 3270
2022
Q4 		$448K Buy
16,296
+1,272
+8% +$33.9K ﹤0.01% 3707
2022
Q3 		$438K Buy
15,024
+2,910
+24% +$100K ﹤0.01% 3787
2022
Q2 		$232K Sell
12,114
-9,626
-44% -$484K ﹤0.01% 4173
2022
Q1 		$1.76M Sell
21,740
-43
-0.2% -$3.54K ﹤0.01% 3313
2021
Q4 		$2M Sell
21,783
-2,024
-9% -$229K ﹤0.01% 3358
2021
Q3 		$2.98M Buy
23,807
+2,509
+12% +$281K ﹤0.01% 3185
2021
Q2 		$2.41M Buy
21,298
+1,382
+7% +$167K ﹤0.01% 3209
2021
Q1 		$3.02M Buy
19,916
+1,439
+8% +$199K ﹤0.01% 3049
2020
Q4 		$2.13M Sell
18,477
-155
-0.8% -$14.2K ﹤0.01% 3051
2020
Q3 		$1.44M Sell
18,632
-1,120
-6% -$91.7K ﹤0.01% 3056
2020
Q2 		$2.17M Buy
19,752
+1,745
+10% +$202K ﹤0.01% 2793
2020
Q1 		$1.97M Buy
18,007
+1,683
+10% +$221K ﹤0.01% 2682
2019
Q4 		$2.59M Buy
16,324
+1,951
+14% +$288K ﹤0.01% 2847
2019
Q3 		$2.12M Buy
14,373
+6,181
+75% +$689K ﹤0.01% 2910
2019
Q2 		$951K Buy
8,192
+2,034
+33% +$191K ﹤0.01% 3255
2019
Q1 		$665K Buy
6,158
+2,467
+67% +$285K ﹤0.01% 3317
2018
Q4 		$300K Buy
3,691
+889
+32% +$108K ﹤0.01% 3557
2018
Q3 		$455K Buy
+2,802
New +$479K ﹤0.01% 3496

Other funds holding VRCA

Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $597M AUM 25.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Salomon & Ludwin
Salomon & Ludwin Richmond, Virginia $1.21B AUM 12.69% 1-Year Est. Return
New England Capital Financial Advisors
New England Capital Financial Advisors Meriden, Connecticut $430M AUM 7.57% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Valley National Advisers
Valley National Advisers Bethlehem, Pennsylvania $909M AUM 22.39% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management's VRCA Position: Q3 2026 in Review

Geode Capital Management reduced its Verrica Pharmaceuticals (VRCA) stake by 7.1% in Q3 2026, selling an estimated $51.4K and leaving 128,298 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Geode Capital Management first reported a position in VRCA in Q3 2018 and has held it in 33 quarters since. The position peaked at $3.38M in Q2 2024. 12 funds tracked by Wall St. Rank hold VRCA as of Q3 2026.

  • Geode Capital Management held 128,298 shares of Verrica Pharmaceuticals worth $615K as of Q3 2026.
  • Geode Capital Management sold 9,862 Verrica Pharmaceuticals shares in Q3 2026, an estimated $51.4K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3487 holding.
  • Geode Capital Management first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 33 quarters since.
  • Geode Capital Management's Verrica Pharmaceuticals position peaked at $3.38M in Q2 2024.
  • 12 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.